Current treatments under investigation for MASLD in T2D, such as GLP-1 receptor agonists (70) and SGLT-2 inhibitors (71), have shown promise in improving liver steatosis and reducing CVD risk and may hold potential for T1D patients. The gene discussed is GLP1R; the disease is Hepatic steatosis.